Floatz logo

Abemaciclib

Translocation Renal Cell Carcinoma

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Translocation Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Bms-907351
Memorial Sloan Kettering Cancer Center
Phase 2B
Palbociclib
Stephanie Berg
Phase 2CCC
Ipilimumab
Bradley A. McGregor, MD
Phase 2CCC
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Axitinib
Stephanie Berg
Phase 2CCC
Cytokine Induced Memory-Like Natural Killer Cells
Dana-Farber Cancer Institute
Early Phase 1C
Sasanlimab
Stephanie Berg
Phase 2C

Same molecule, other indications

Abemaciclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Hormone Receptor Positive TumorDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →